Condition
Myelomatosis
Total Trials
4
Recruiting
0
Active
1
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
200%
2 of 1 completed with results
Key Signals
2 with results33% success
Data Visualizations
Phase Distribution
4Total
P 1 (3)
P 2 (1)
Trial Status
Terminated2
Active Not Recruiting1
Completed1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05153330Phase 1Terminated
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
NCT04782687Phase 2Active Not Recruiting
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
NCT02057640Phase 1Completed
MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
NCT01239368Phase 1Terminated
Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma
Showing all 4 trials